TY - JOUR T1 - COVID-19 herd immunity strategies: walking an elusive and dangerous tightrope JF - medRxiv DO - 10.1101/2020.04.29.20082065 SP - 2020.04.29.20082065 AU - Tobias S Brett AU - Pejman Rohani Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/05/2020.04.29.20082065.abstract N2 - The rapid growth in cases of COVID-19 has threatened to overwhelm healthcare systems in multiple countries. In response, severely affected countries have had to consider a range of public health strategies achieved by implementing non-pharmaceutical interventions. Broadly, these strategies have fallen into two categories: i) “mitigation”, which aims to achieve herd immunity by allowing the SARS-CoV-2 virus to spread through the population while mitigating disease burden, and ii) “suppression”, aiming to drastically reduce SARS-CoV-2 transmission rates and halt endogenous transmission in the target population. Using an age-structured transmission model, parameterised to simulate SARS-CoV-2 transmission in the UK, we assessed the prospects of success using both of these approaches. We simulated a range of different non-pharmaceutical intervention scenarios incorporating social distancing applied to differing age groups. We found that it is possible to suppress SARS-CoV-2 transmission if social distancing measures are sustained at a sufficient level for a period of months. Our modelling did not support achieving herd immunity as a practical objective, requiring an unlikely balancing of multiple poorly-defined forces. Specifically, we found that: i) social distancing must initially reduce the transmission rate to within a narrow range, ii) to compensate for susceptible depletion, the extent of social distancing must be vary over time in a precise but unfeasible way, and iii) social distancing must be maintained for a long duration (over 6 months).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is funded by the National Institute of Health through a MIDAS (Models of infectious disease agent study) grant 5R01GM123007.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data used in this study are available at https://github.com/tsbrett/COVID-19_herd_immunity/releases/tag/v1.0https://github.com/tsbrett/COVID-19_herd_immunity/releases/tag/v1.0 ER -